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In 2004, Malawi began scaling up its national antiretroviral therapy (ART) program. Because of limited
treatment options, population-level surveillance of acquired human immunodeficiency virus drug resistance
(HIVDR) is critical to ensuring long-term treatment success. The World Health Organization target for clinic-
level HIVDR prevention at 12 months after ART initiation is ‡70%. In 2007, viral load and HIVDR genotyping
was performed in a retrospective cohort of 596 patients at 4 ART clinics. Overall, HIVDR prevention (using
viral load £400 copies/mL) was 72% (95% confidence interval [CI], 67%–77%; range by site, 60%–83%) and
detected HIVDR was 3.4% (95% CI, 1.8%–5.8%; range by site, 2.5%–4.7%). Results demonstrate virological
suppression and HIVDR consistent with previous reports from sub-Saharan Africa. High rates of attrition
because of loss to follow-up were noted and merit attention.
In June 2004, Malawi began scaling up its national an-
tiretroviral therapy (ART) program, rapidly increasing
the number of patients initiated on ART from 13 183 in
2004 to 271 105 by December 2009. Individuals infected
with human immunodeficiency virus (HIV) with World
Health Organization (WHO) clinical stage III or IV
disease or with a CD4 cell count ,250/lL (increased
from 200/lL in 2007) are eligible for free ART in
Malawi. After initiation, patients visit ART clinics
monthly for clinical monitoring and drug collection
until they are stable, at which time visit frequency
decreases to once every 2–3 months.
At the time this survey was conducted, 1 standard
first-line ART regimen consisting of nevirapine (NVP)
in combination with stavudine and lamivudine (3TC)
and alternative first-line regimens containing efavirenz
(EFV) and/or zidovudine (ZDV) were used within the
national program. Additionally, 1 second-line combi-
nation of ZDV, 3TC, tenofovir (TDF), and lopinavir/
ritonavir was available [1].
Because of the need for lifelong treatment and HIV’s
high mutation rate, virological failure and emergence of
HIV drug resistance (HIVDR) among populations re-
ceiving ART is inevitable. National treatment programs
in sub-Saharan Africa have observed levels of virological
failure varying between 14% and 53% within the first
6–24 months after treatment initiation [2–8]. Studies
show that among individuals with virological failure
receiving ART from the national ART programs, the
presence of at least 1 HIVDR mutation varied widely
from 44% to 100% [3–15].
At present, individual patient HIVDR testing is not
feasible in Malawi due to its high cost and the lack of
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adequate laboratory infrastructure. Therefore, surveillance of
population-level HIVDR and identification of ART program
factors, which can be adjusted to minimize emergence of
HIVDR and optimize treatment outcomes, are essential. In
2005, the Malawi Ministry of Health created an HIVDR Task
Force and adopted the WHO strategy for assessing trans-
mitted and acquired HIVDR and monitoring HIVDR early
warning indicators (EWIs) in resource-limited countries
[16–19]. In December 2006, Malawi completed its first survey
of transmitted HIVDR that classified transmitted drug re-
sistance in the capital Lilongwe as low (,5%) to nucleoside
reverse transcriptase inhibitors, nonnucleoside reverse tran-
scriptase inhibitors (NNRTIs), and protease inhibitors [20]. In
2007, Malawi’s first HIVDR EWI report documented that most
clinics monitored achieved WHO targets for relevant indicators
except for patient retention on first-line ART at 12 months,
which was achieved by less than half of clinics [21].
In this article we describe results from a retrospective survey
of HIVDR performed in patients on ART at 4 clinics in Malawi.
This survey was performed in 2007 on cohorts of patients
initiating first-line ART 12 months previously.
METHODS
We used a retrospective method to assess acquired HIVDR and
associated program factors in populations of patients on ART
for 12 months. This retrospective methodology was endorsed by
the WHO in 2006 for the HIVDR Monitoring Survey, although
the later standard versions of the WHO protocol only include
prospective cohort surveys [18]. The survey was approved by
the National Health Sciences Research Committee of Malawi,
and informed consent was obtained from survey participants
who were alive and attended a 12-month clinic appointment
falling between 11 and 15 months after ART initiation.
Clinics Surveyed
Four ART clinics in Malawi were selected for this survey (3 of
them central hospitals): Queen Elizabeth Central Hospital
(QECH), Blantyre; Mzuzu Central Hospital, Mzuzu; Lighthouse
Clinic at Kamuzu Central Hospital, Lilongwe; and Thyolo
District Hospital, Thyolo. These clinics were chosen because
they were among the first ART clinics in Malawi, could pro-
vide sufficient sample sizes, had the capacity to identify selected
patients during routine follow-up visits, and had facilities to
collect and store plasma specimens on site.
Survey Participants and Procedures
In March 2007, we retrospectively identified cohorts of patients
who had initiated first-line ART 12 months prior (in February
2006) at each of the 4 clinics. The target sample size for each
clinic (n 5 96) provided a 95% confidence interval 6 10%
regardless of the cumulative incidence of viral load (VL)
suppression, as per the WHO protocol [18]. The actual sample
size was increased to accommodate for expected attrition due to
death and transfers to other clinics (transfers out).
Different expected attrition rates based on previous reports
at each site resulted in varying sample sizes (Mzuzu Hospital,
n 5 143; Lighthouse Clinic, n 5 145; QECH, n 5 148; and
Thyolo Hospital, n 5 160). Patients aged $15 years and ini-
tiating ART for the first time (not transferring in from another
clinic) were consecutively sampled for the cohorts until the
target sample size was reached. Sampling was independent of
actual outcomes after treatment initiation.
For each patient, relevant demographic data were abstracted
from medical records, including tuberculosis status, WHO
clinical stage, CD4 cell count, VL at the start of ART, and ART
regimen prescribed. Additionally, dates of clinical appoint-
ments, number of appointments with pill count completed,
and number of appointments with a pill count and at least
95% adherence were abstracted to estimate adherence to
prescribed ART. All patients were classified into one of the
following survey endpoints: on first-line ART, stopped ART,
switched to and on second-line ART, dead, transferred out,
or lost to follow-up. As information on exposure to anti-
retroviral drugs prior to initiation of ART at the clinic was
generally not available in routine medical records, a brief
questionnaire was administered.
In 3 of the 4 clinics, CD4 cell counts were routinely performed
12 months after ART initiation. Plasma specimens for VL and
HIVDR genotyping were prepared from remnant blood ob-
tained from routine CD4 cell count specimens except at QECH,
where routine CD4 counts were not performed during the
survey period. At QECH a specimen was drawn for the sole
purpose of this survey. Plasma specimens were stored on site
at 280C until transportation on ice packs for storage at the
HIV reference laboratory at the Community Health Sciences
Unit in Lilongwe. At the end of the survey, all specimens were
shipped on dry ice to the National Institute for Communicable
Diseases in Johannesburg, South Africa, for VL determination
and HIVDR genotyping.
HIV RNA and HIVDR Genotyping
HIV RNA testing was performed using the Roche COBAS
Amplicor automated system, per manufacture instructions.
A previously described broadly sensitive in-house assay
for HIV pol sequencing was used for genotypic resistance
testing and performed on all specimens with HIV RNA
.400 copies/mL [22].
Data Analysis
The total eligible population for analysis was defined as pa-
tients alive and on ART and from whom a useable specimen
was collected or patients classified as lost to follow-up or who
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stopped treatment. Individuals who died, those who trans-
ferred out, and those without 12-month specimens or who
had unusable specimens were excluded. Survey participants
were classified into one of three 12-month HIVDR outcome
classifications: (1) HIVDR prevention: on first-line ART and
VL #400 copies/mL; (2) possible HIVDR: on ART with VL
.400 copies/mL and no detected HIVDR, or classified as lost
to follow-up or stopped treatment; (3) detected HIVDR: on
ART with VL .400 copies/mL and detected mutations caus-
ing low-, intermediate-, or high-level resistance to$1 relevant
drugs per the Stanford HIV database [23].
The WHO survey of acquired HIVDR defines VL suppression
as #1000 copies/mL [18]; however, we chose a more stringent
threshold of VL#400 copies/mL. Numerators and denominators
of HIVDR outcomes are defined in Supplementary Table 1.
Patient characteristics were compared across clinics and
outcome groups using analysis of variance, Fisher exact test,
Wilcoxon rank-sum test, and k sample equality of medians test,
as appropriate. All analyses were performed using Stata/MP
software, version 11 (StataCorp).
RESULTS
A total of 596 individuals meeting survey inclusion criteria were
identified as having consecutively initiated first-line ART at the
4 clinics, and all were classified into survey endpoints. Patient
characteristics at time of ART initiation are summarized in
Table 1. All patients at each of the 4 sites had initiated standard
first-line ART; 60% of individuals were female, and the mean
age of the cohort was 36.3 years (standard deviation, 9.5 years).
Rates of tuberculosis infection within the last 2 years varied
significantly by clinic, from 7% at Mzuzu Central Hospital to
24% at QECH (P , .01). WHO clinical stage at initiation also
varied by clinic, with more patients initiating ART with WHO
clinical stages I and II (18%) atMzuzu Central Hospital compared
with the other 3 sites (P , .01). CD4 counts prior to ART ini-
tiation were available for 73% (436 of 596) of patients sampled,
ranging from 17% at QECH to 99.4% at Thyolo. Median CD4
at ART initiation was 116 (interquartile range [IQR], 54–203)
cells/lL. Pretreatment VLs were only available from Mzuzu
(median VL, 396 508 copies/mL; IQR, 117 540–976 800).
Figure 1 summarizes 12-month endpoints and HIVDR out-
comes, and clinic-specific results are presented in Table 2. Of the
596 patients, 117 of 596 (20%) transferred to another site before
the 12-month follow-up date. Overall, there was high early
mortality with 64 deaths (11%) within the first year of ART. In
total, 44 of 64 deaths (69%) occurred within the first 3 months
after ART initiation. Five (0.8%) patients, all at Lighthouse
Clinic, stopped treatment, and 79 (13%) were lost to follow-up
during the first 12 months after ART initiation. Rates of loss to
Table 1. Baseline Demographic Characteristics by Site
Characteristics Mzuzu (n 5 143a)
Lighthouse
(n 5 148b)
QECH
(n 5 145c)
Thyolo
(n 5 160d) Total
Female 79 (55%) 96 (65%) 88 (61%) 95 (60%) 358 (60%)
Mean age, years (SD) 37.9 (10.2) 35.6 (9.9) 36.7 (8.7) 35.2 (9.2) 36.3 (9.5)
Tuberculosis
(current or within past 2 years)e
10 (7%) 23 (16%) 35 (24%) 26 (16%) 94 (16%)
WHO clinical stage I or IIe 26 (18%) 15 (10%) 12 (8%) 7 (4%) 60 (10%)
WHO clinical stage III 83 (58%) 102 (69%) 101 (71%) 129 (81%) 415 (70%)
WHO clinical stage IV 34 (24%) 30 (20%) 30 (21%) 24 (15%) 118 (20%)
Median CD4 count (IQR) prior
to ART initiation
129 (94–202) 114 (40–232) 132 (90–199) 100 (42–184) 116 (54–203)
Median viral load (IQR) prior to
ART initiation
396 508 (177 540–976 800) Not measured Not measured Not measured 396 508 (177 540–976 800)
Previous ART exposure
Questionnaire administered 83 53 67 61 264
PMTCT exposure prior to
initiation
1 (1%) 5 (10%) 0 (0%) 3 (2%) 9 (3%)
Other ART exposure prior to
initiation
0 (0%) 1 (2%) 4 (6%) 0 (0%) 5 (2%)
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; PMTCT, prevention of mother-to-child transmission; QECH, Queen Elizabeth Central Hospital;
WHO, World Health Organization.
a Baseline CD4 count missing for 18 patients; baseline viral loads missing for 3 patients.
b WHO stage missing for 1 patient; baseline CD4 count missing for 21 patients.
c WHO stage missing for 2 patients; baseline CD4 count only available for 25 patients.
d Age and sex missing for 1 patient.
e P , .01.
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follow-up varied by site, ranging from 4% in Thyolo to 20% in
Mzuzu. At the end of the first year of ART, 331 of 596 (56%)
patients were alive and on first-line ART, ranging from 46% at
Thyolo to 66% at QECH. No patient switched to the second-
line ART during the course of the survey. First-line ART
substitutions for reasons of toxicity or adverse effects did
occur during the first 12 months for 12 patients: 2 at Mzuzu,
4 at Thyolo, and 6 at QECH.
Of the 331 patients alive and on ART after 12 months, 53 of
331 (16%) did not have specimens collected for VL testing and
were subsequently excluded from analyses (Figure 1). Of the 278
patients with endpoint specimens, 264 completed the ques-
tionnaire about previous antiretroviral drug exposure. In total,
14 of 264 (5.3%) reported exposure to any antiretrovirals prior
to initiating first-line ART at the clinic; 9 of 14 (64%) were
women who had received NVP for the prevention of mother-to-
child transmission (Table 1).
Of the specimens collected, 8 of 278 (2.9%) were not suitable
for testing due to hemolysis or insufficient quantity; 255 of 270
(94.4%) with usable specimens 12 months after ART initiation
had VL #400 copies/mL. Of the 15 of 270 (5.5%) patients with
VL .400 copies/mL, 12 of 15 (80%) had at least 1 HIVDR
mutation (Supplementary Table 2). All 12 had high-level re-
sistance to NVP and varying levels of EFV resistance (42% high-,
17% intermediate-, and 42% low-level resistance) mainly due
to the Y181C mutation. Nine (75%) patients had M184V
conferring high-level resistance to 3TC, and 1 patient had
K65R associated with didanosine and TDF resistance. All se-
quences clustered with HIV subtype C.
HIVDR prevention varied among clinics: 60% at Lighthouse,
68% at Mzuzu, 79% at QECH, and 83% at Thyolo. These dif-
ferences were largely driven by the differences in loss to follow-
up rates. Detected HIVDRwas 3.4%, ranging from 2.5% to 4.7%
by clinic. Possible HIVDR was considerably higher than de-
tected resistance, ranging from 13.6% at Thyolo to 37.5% at
the Lighthouse Clinic.
Factors associated with virological failure are presented in
Supplementary Table 3. The only significant association was age
at initiation of ART (30.7 in those with VL .400 copies/mL vs
37.4 years in those with VL #400 copies/mL; P , .05). We also
compared those lost to follow-up or who stopped ART (n5 84)
with those who died (n 5 64). No differences were observed
between the 2 groups with regard to sex (female, 54% vs 49%;
P 5 .62), mean age (35.3 vs 35.8 years; P 5 .74), tuberculosis
infection within the last 2 years (19% vs 20%; P ..99), and
median VL at ART initiation (415 600 vs 428 000; P ..99).
However, there were differences in WHO clinical stage at
initiation (24% in stage IV for lost to follow-up/stopped pa-
tients and 45% for those who died; P, .05) and baseline CD4
(median baseline CD4 for lost to follow-up/stopped patients
was 127 compared with 44 for those who died; P, .01). Median
times from initiation of first-line ART to the outcomes of either
death or loss to follow-up were 2 months (IQR, 1–5months) and
6 months (IQR, 4–11 months) (P , .01), respectively.
DISCUSSION
Overall, we observed a low rate of detected HIVDR (3.4%)
among adult patients in Malawi receiving ART for 12 months at
4 clinics in the national ART program. However, the rate of
possible HIVDR was high (24.6%, varying per site from 13.6%
to 37.5%), indicating that the true rate of resistance may be
higher than detected. High possible HIVDR was driven by the
relatively high rate of loss to follow-up. These patients were
classified as possible HIVDR because if they were to reinitiate
first-line ART, they would have a considerable chance of having
HIVDR to 1 or more components of current first-line regimen
due to treatment interruption [14]. If patients who were lost to
follow-up were censored from the analysis, estimated rates of
possible HIVDR decreased to 2.9% (range by site, 0–10.7%)
with a slight increase in the rate of detected HIVDR (4.4%; range
by site, 3.3%–6.5%). The most appropriate handling of loss to
follow-up remains unclear, as evidence from Malawi suggests
that a substantial proportion of individuals who default from
care in the first 4 months of initiation have in fact died [24].
However, there was a significant difference in the baseline WHO
clinical stage and CD4 counts, suggesting that these groups
should be handled differently in the analysis.
Due to limited resources and lack of laboratory capacity, few
ART clinics in Malawi offer routine VL monitoring to detect
Figure 1. Survey overview. Only 1 patient had viral load of 400–1000
copies/mL; this specimen was genotyped and had detected human
immunodeficiency virus drug resistance. Abbreviations: HIV, human
immunodeficiency virus; HIVDR, HIV drug resistance.
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Table 2. Twelve-Month Survey Endpoints by Site
Outcomes Mzuzu (n 5 143) Lighthouse (n 5 148) QECH (n 5 145) Thyolo (n 5 160) Total (n 5 596)
Dead 12 (8%) 17 (11%) 17 (12%) 18 (11%) 64 (11%)
Lost to follow-up 28 (20%) 24 (16%) 20 (14%) 7 (4%) 79 (13%)
Transferred out 14 (10%) 28 (19%) 13 (9%) 62 (39%) 117 (20%)
Stopped ART 0 (0%) 5 (3%) 0 (0%) 0 (0%) 5 (1%)
On first-line ART at 12 months 89 (62%) 74 (50%) 95 (66%) 73 (46%) 331 (56%)
No specimen collected 6 22 5 20 53
If alive, specimen collected 83/89 (93%) 52/74 (70%) 90/95 (95%) 53/73 (73%) 278/331 (84%)
Usable specimens 77/83 (93%) 51/52 (98%) 90/90 (100%) 52/53 (98%) 270/278 (97%)
HIV RNA .400 copies/mLa 6 3 3 3 15
HIVDR detected 5 2 3 2 12
Total eligible population for analysis
(total sample size excluding those
who died, transferred, or
had no usable specimen)
105 80 110 59 354
HIVDR prevention (VL #400 copies/mL) 71 48 87 49 255
95% CI 67.6% (57.8%–76.4%) 60.0% (48.4%–70.8%) 79.1% (70.2%–86.3%) 83.1% (71.0%–91.6%) 72.0% (67.0%–76.6%)
Possible HIVDR 29 30 20 8 87
Possible HIVDR rate (95% CI) 27.6% (19.3%–37.2%) 37.5% (26.9%–49.0%) 18.2% (11.5%–26.7%) 13.6% (6.0%–25.0%) 24.6% (20.2%–29.4%)
Detected HIVDR 5 2 3 2 12
Detected HIVDR rate (95% CI) 4.7% (1.6%–10.8%) 2.5% (0.3%–8.7%) 2.7% (0.6%–7.8%) 3.4% (0.4%–11.7%) 3.4% (1.8%–5.8%)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HIVDR, HIV drug resistance; QECH, Queen Elizabeth Central Hospital; VL, viral load.
a Used more stringent cutoff of #400 copies/mL instead of #1000 copies/mL recommended by the World Health Organization.
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virological failure; thus most patients are monitored by clinical
means only, sometimes with CD4 counts. In those who fulfill
clinical and/or immunological failure criteria, VL measurement
is required to confirm failure to minimize misclassification
and inappropriate switch to second-line regimens. Individual
HIVDR testing is widely used in high-income countries to
determine optimal second-line regimens. However, the cost
and complexity of HIVDR genotyping preclude its routine use
in Malawi outside of surveillance and research settings. Fur-
thermore, interpretation of individual HIVDR test results is
often not straightforward and may be challenging, especially
in peripheral clinics where primary care has been shifted to
nurses or clinical officers who have not had training in
HIVDR interpretation.
In this study, patients with virological failure and detected
HIVDR had expected mutations to 3TC and NNRTIs
(Supplementary Table 2). Interestingly, no thymidine ana-
logue mutations were detected, suggesting fairly recent onset of
virological failure [16]. Unlike in this survey, complex and
extensive HIVDR has been observed in Malawian adults en-
rolled in the national ART program when ART failure is
identified using clinical and immunological criteria [9].
However, such patients likely had virological failure for much
longer periods of time before HIVDR genotyping than did
patients in this survey.
It is noteworthy that only 3 of 15 (20%) patients with viro-
logical failure at 12 months had no detected HIVDR, suggesting
high population-level adherence to ART among those retained
on ART. This finding is juxtaposed to a similar WHO survey of
acquired HIVDR conducted in Burundi, where the majority of
patients experiencing virological failure at 12 months had no
detected HIVDR [25]. The resulting public health response
should be different in these 2 settings.
One strength of this survey of acquired HIVDR is that it was
integrated into routine care delivery at each of the 4 clinics to
obtain data reflecting real-life scenarios and to minimize burden
on patients and clinic staff. However, because it was not set up
as a research study, identifying the preselected patients at
their 12-month appointments and collecting specimens from
them was challenging. Of the 331 patients alive after 12 months
of ART, 53 attended their 12-month appointment but were not
included in the survey due to logistical challenges at the clinics.
A further 8 had specimens that could not be amplified for
genotyping. There were no significant differences in baseline
characteristics between those for whom usable specimens
were obtained and the 61 subjects that were excluded from
analysis (data not shown), suggesting that missed or compro-
mised specimens were not related to treatment outcomes.
However, entirely excluding these from analysis potentially
inflates the estimate of possible HIVDR. Additionally, because
of the retrospective methodology, we could only explore the
relationship between virological failure/HIVDR and routinely
collected variables. Relevant factors such as on-time clinic
attendance, on-time pill pickup, and HIVDR prior to ART
initiation could not be assessed because data were not avail-
able in medical records and remnant pretreatment specimens
were not available for HIVDR genotyping. Additionally, we
could not assess virological suppression among patients
transferring to other health centers, and the number trans-
ferring was large due to the national policy of stimulating
decentralization of care. Finally, clinics monitored in this
survey were selected because of their capacity to implement
the survey and therefore are not intended to be representative
of Malawi’s entire ART program.
CONCLUSIONS
This retrospective survey of acquired HIVDR among patients
on ART for 12 months suggests that these 4 clinics are
achieving high rates of VL suppression among patients re-
tained on ART and low rates of detected HIVDR. However,
possible HIVDR was high due to high rates of loss to follow-up.
Routine population-level surveillance of acquired HIVDR and
identification of associated program factors is critical to ensure
long-term efficacy of currently available first- and second-line
ART.
As a result of this survey and other program monitoring
data, Malawi plans to implement operational research to de-
fine reasons for loss to follow-up to develop appropriately
targeted interventions. Finally, although WHO, the US Presi-
dent’s Emergency Plan for AIDS Relief (PEPFAR), and the
Centers for Disease Control and Prevention initially depriori-
tized retrospective surveillance of HIVDR as was implemented
in Malawi, this method is likely less expensive and time-
consuming than a prospective design, and we encourage re-
introduction of this design. Recently, the WHO, along with
PEPFAR, has developed a new cross-sectional survey to assess
HIVDR at representative ART clinics within countries, which
will be piloted in 2012 and may provide another feasible al-
ternative to the prospective surveillance of acquired resistance.
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